Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies

Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies

Mass SARS-Cov-2 vaccination campaign represents the only strategy to defeat the global pandemic we are facing. Immunocompromised patients represent a vulnerable population at high risk of developing severe COVID-19 and thus should be prioritized in the vaccination programs and in the study of the va...

Full description

Bibliographic Details
Main Authors: Donato Amodio, Alessandra Ruggiero, Mayla Sgrulletti, Chiara Pighi, Nicola Cotugno, Chiara Medri, Elena Morrocchi, Luna Colagrossi, Cristina Russo, Salvatore Zaffina, Gigliola Di Matteo, Cristina Cifaldi, Silvia Di Cesare, Beatrice Rivalta, Lucia Pacillo, Veronica Santilli, Carmela Giancotta, Emma Concetta Manno, Marta Ciofi Degli Atti, Massimiliano Raponi, Paolo Rossi, Andrea Finocchi, Caterina Cancrini, Carlo Federico Perno, Viviana Moschese, Paolo Palma
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Immunology
Subjects:
BNT162b2 mRNA COVID-19 vaccine
Comirnaty
SARS-CoV-2
COVID-19
inborn errors of immunity
vaccine efficacy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.727850/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.727850/full

Similar Items